Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual ?-cell function in recent-onset type 1 diabetes.
Demeester S, Keymeulen B, Kaufman L, Van Dalem A, Balti EV, Van de Velde U, Goubert P, Verhaeghen K, Davidson HW, Wenzlau JM, Weets I, Pipeleers DG, Gorus FK. Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual ?-cell function in recent-onset type 1 diabetes. Diabetes Care. 2015 Apr; 38(4):644-51.